Information Provided By: 
Fly News Breaks for July 10, 2015
LLY
Jul 10, 2015 | 08:08 EDT
Leerink says the FDA Oncologic Drugs Advisory Committee meeting on Eli Lilly's necitumumab for 1st-line squamous non small cell lung cancer delivered "generally positive views" on the drug's benefit/risk assessment. While no vote was taken, the firm believes the meeting suggests FDA approval is likely on or before the August 30 action date. Leerink has an Outperform rating on Lilly.
News For LLY From the Last 2 Days
There are no results for your query LLY
